Abstract: Provided are compositions and methods useful for duplicating/amplifying a target fragment on a target DNA sequence such as a genome sequence. The editing system employs a pair of pegRNA which, by virtue of their targeting sites flanking the target fragment, extend the target fragment with reverse transcriptase (RT) templates included in the pegRNA. As the two RT templates at least include portions that are complementary to each other, they can form a duplex region which can then serve as starting point for DNA polymerase to synthesize a new strand for each strand of the target fragment, thereby duplicating the target fragment. Continue this process introduce amplification of this targeted sequence. Alternatively, this process can be done by combination of pegRNA/sgRNA or sgRNA/sgRNA. In the case of sgRNA/sgRNA in a PAM-out position, the RT enzyme and templates are not required.

Abstract: Systems, devices, and methods for fabricating staircase structures in three-dimensional (3D) semiconductor devices are provided. In one aspect, a method includes providing a first deck comprising a first stack of first sacrificial layers and first isolating layers extending along a first direction. At least a part of the first deck is etched to form a first staircase structure. A second deck adjacent to the first deck along a second direction is provided, the second deck comprising a second stack of second sacrificial layers and second isolating layers extending along the first direction, the second sacrificial layers and the second isolating layers alternating with each other along the second direction. At least a part of the second deck is etched to form a second staircase structure. Contact structures extending through at least one of the first staircase structure or the second staircase structure along the second direction are formed.

Abstract: The invention relates to a T cell expressing an antibody or comprising the coding sequence of the antibody or an expression vector thereof; the antibody contains an optional signal peptide, an antigen binding sequence and a mutant type Fc segment, wherein the mutant type Fc segment is a Fc segment in which amino acid residues at the 17th site and the 79th site of the IgG4 Fc segment shown by SEQ ID NO: 25 are mutated into E and Q respectively. Preferably, the T cell is a CAR-T cell. The present invention further relates to a treatment application of the T cell in malignant tumors.

Abstract: Three-dimensional (3D) memory devices and fabricating methods thereof are disclosed. The disclosed semiconductor device can comprise a stack structure comprising alternative conductive layers and dielectric layers, and a gate line structure extending vertically through the stack structure and laterally along a first lateral direction to divide the stack structure into memory fingers. The gate line structure can comprise gate line slit structure segments aligned along the first lateral direction, and at least one first dummy contact structure located between adjacent gate line slit structure segments in the first lateral direction.

Abstract: Three-dimensional (3D) memory devices and fabricating methods thereof are disclosed. A disclosed semiconductor device comprises a stack structure comprising alternative conductive layers and dielectric layers, and a gate line structure extending vertically through the stack structure and laterally along a first lateral direction to divide the stack structure into memory blocks. The gate line structure comprises gate line slit structure segments aligned along the first lateral direction, and at least one dummy channel structure located between the gate line slit structure segments in the first lateral direction.

Abstract: Three-dimensional (3D) memory devices and fabricating methods thereof are disclosed. One disclosed semiconductor device comprises a stack structure comprising an array region and a contact region, and a gate line slit structure extending vertically through the stack structure and laterally along a first lateral direction to divide the stack structure into memory blocks. The gate line slit structure comprises a first dummy channel structure located at a boundary between the array region and the contact region, a first gate line slit segment extending laterally from the first dummy channel structure into the array region, and a second gate line slit segment extending laterally from the first dummy channel structure into the contact region.

Abstract: Implementations of three-dimensional (3D) memory devices and fabricating methods thereof are disclosed. In some implementations, the disclosed 3D memory device comprises: a stack structure including a plurality of dielectric layers and conductive layers alternatively stacked in a vertical direction; an array of channel structures each vertically penetrating the stack structure, each channel structure including a functional layer and a channel layer; and a plurality of isolation structures extending in parallel along a first lateral direction and vertically in an upper portion of the stack structure, each isolation structure being in contact with the channel layers of two adjacent rows of channel structures.

Abstract: A semiconductor device includes a stack comprising interleaved conductive layers and dielectric layers stacked along a first direction, and a contact structure extending through the stack along the first direction. The conductive layers include a first conductive layer and a second conductive layer under the first conductive layer, and the first conductive layer is in contact with the contact structure. The first conductive layer includes a first portion having a first thickness and a second portion having a second thickness less than the first thickness in contact with the contact structure.

Abstract: A culture composition for expanding a TIL, containing IL-2, IL-7, IL-15, and an immune checkpoint antibody or an antigen-binding fragment thereof. The immune checkpoint antibody comprises any one or more of a PD-1 antibody, a CTLA-4 antibody, a LAG-3 antibody, a TIM-3 antibody, a TIGIT antibody, and a BTLA antibody. The present invention further relates to a TIL expanding culture medium, a method for preparing a TIL population, and a pharmaceutical composition. In the culture composition, cell proliferation and activity are ensured while greatly reducing the used amount of IL-2, and IL-2 treatment is removed after infusing the TILs obtained using the culture composition into a patient so as to reduce side effects; moreover, no feeder cells are used in an expansion process, exogenous pollution is reduced and the manufacturing process is simplified, the manufacturing costs reduced, and the manufacturing time shortened.

Abstract: Provided are compositions and methods useful for inserting a larger nucleic acid fragment to a target genome sequence. The editing system employs a pair of pegRNA which, by virtue of their targeting nearby genomic sites and having sequences complementary to each other, collectively form a template for inserting a large exogenous sequence to the target genomic locus.

Abstract: Provided is a transgenic killer cell, the genome of which is stably integrated with a coding sequence comprising an antibody of a human Fc section, or an expression cassette of a coding sequence comprising a chimeric antigen receptor or an inhibitory or agonistic antibody, and an inverted terminal repeat sequence from a transposon at both ends. Also provided is a pharmaceutical composition comprising the transgenic killer cell, and uses thereof.

Abstract: A pharmaceutical composition, containing chloroquine or a derivative thereof and a tumor cell killing agent, and a pharmaceutically acceptable excipient. Also provided is a use of chloroquine or a derivative thereof in preparation of a medication for treating a tumor.

Abstract: A seed cell medium of a tumor-infiltrating lymphocyte and an application thereof. The medium contains a cell culture component, a cell factor, and an immune checkpoint antibody or an antigen-binding fragment thereof. The cell factor includes IL-2; an immune checkpoint includes PD-1, LAG-3, TIGIT, and/or CTLA-4; and the cell culture component is a serum medium or a serum-free medium. The seed cell medium accelerates a culture of a seed cell of the tumor-infiltrating lymphocyte and shortens the amplification time required by the tumor-infiltrating lymphocyte.

Abstract: The present invention relates to the method and the system for initializing secure network access for POS terminals. Said system comprises a terminal backend system and a POS terminal. The POS terminal is provided with: a security module, which was preloaded with a terminal default public key certificate, a private key file, and a CA public key certificate of the terminal backend system in the setting of leaving the factory; a transaction module, which is used for performing the acquiring operation with the following core trading module; and a parameter initializing module, which is used for implementing network access.

Abstract: A lithium-ion battery non-aqueous electrolyte and a lithium-ion battery. The non-aqueous electrolyte comprises at least one selected from the compounds represented by structural formula I and II; in formula I, R1 and R2 are independently selected from alkenyl having 2-5 carbon atoms and alkynyl having 2-5 carbon atoms; in formula II, R3 is selected from alkenyl having 2-5 carbon atoms and alkynyl having 2-5 carbon atoms.

Abstract: The invention relates to a T cell expressing an antibody or comprising the coding sequence of the antibody or an expression vector thereof; the antibody contains an optional signal peptide, an antigen binding sequence and a mutant type Fc segment, wherein the mutant type Fc segment is a Fc segment in which amino acid residues at the 17th site and the 79th site of the IgG4 Fc segment shown by SEQ ID NO: 25 are mutated into E and Q respectively. Preferably, the T cell is a CAR-T cell. The present invention further relates to a treatment application of the T cell in malignant tumors.

Abstract: Provided is a chimeric promoter with a high transcriptional activity in T-cells. The chimeric promoter consists of an enhancer sDTS and a promoter operably linked to the enhancer. The sequence of the enhancer is as shown in SEQ ID NO: 1. The enhancer is located at the 5? or 3? terminus of the promoter. Also provided are nucleic acid constructs, vectors and T-cells comprising the chimeric promoter. The chimeric promoter can drive the efficient expression of exogenous genes in T-cells.

Abstract: Provided is a transgenic killer cell, the genome of which is stably integrated with a coding sequence comprising an antibody of a human Fc section, or an expression cassette of a coding sequence comprising a chimeric antigen receptor or an inhibitory or agonistic antibody, and an inverted terminal repeat sequence from a transposon at both ends. Also provided is a pharmaceutical composition comprising the transgenic killer cell, and uses thereof.

Abstract: A lithium-ion battery non-aqueous electrolyte and a lithium-ion battery. The non-aqueous electrolyte comprises at least one selected from the compounds represented by structural formula I and II; in formula I, R1 and R2 are independently selected from alkenyl having 2-5 carbon atoms and alkynyl having 2-5 carbon atoms; in formula II, R3 is selected from alkenyl having 2-5 carbon atoms and alkynyl having 2-5 carbon atoms.

Abstract: The present invention relates to the method and the system for initializing secure network access for POS terminals. Said system comprises a terminal backend system and a POS terminal. The POS terminal is provided with: a security module, which was preloaded with a terminal default public key certificate, a private key file, and a CA public key certificate of the terminal backend system in the setting of leaving the factory; a transaction module, which is used for performing the acquiring operation with the following core trading module; and a parameter initializing module, which is used for implementing network access.